Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel® in head-to-head Phase
Novartis International AG / Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel® in head-to-head Phase III psoriasis study . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible …